Literature DB >> 26351924

Relationship between matrix metalloproteinase-9 and oxidative stress in drug-free male schizophrenia: a case control study.

Sivasankar Devanarayanan, Hanumanthappa Nandeesha, Shivanand Kattimani, Siddharth Sarkar.   

Abstract

BACKGROUND: Deregulation of synaptic plasticity and oxidative stress are reported to play a crucial role in the pathogenesis of schizophrenia. Matrix metalloproteinase-9 (MMP-9) is an extracellular protease involved in regulation of synaptic plasticity. Malondialdehyde (MDA) is a marker of lipid peroxidation which is elevated in schizophrenia. Earlier studies have reported polymorphism of MMP-9 and its association with schizophrenia. The present study was designed to assess the serum levels of MMP-9, MDA and total antioxidant status (TAS) and their association in schizophrenia.
METHODS: A total of 40 cases and 40 controls were included in the study. Serum MMP-9, MDA and TAS were estimated in all the subjects. Disease severity was assessed using Positive and Negative Syndrome Scale (PANSS).
RESULTS: MMP-9 and MDA were significantly increased and TAS were significantly reduced in schizophrenia cases compared to controls. MMP-9 was positively correlated with MDA (r=0.353, p=0.025) and negatively correlated with TAS (r=-0.461, p=0.003). TAS was significantly correlated with total (r=0.322, p=0.043) and negative symptom scores (r=0.336, p=0.034). Higher MMP-9 levels were associated with previous exposure to antipsychotics (p=0.032).
CONCLUSIONS: MMP-9 and oxidative stress were increased and correlate well with each other in schizophrenia cases. Though total oxidant status showed positive association with disease severity, MMP-9 and MDA were not associated with the severity of the disease.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26351924     DOI: 10.1515/cclm-2015-0212

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  11 in total

1.  Oxidative stress in drug-naïve first episode patients with schizophrenia and major depression: effects of disease acuity and potential confounders.

Authors:  Wolfgang Jordan; Henrik Dobrowolny; Sabine Bahn; Hans-Gert Bernstein; Tanja Brigadski; Thomas Frodl; Berend Isermann; Volkmar Lessmann; Jürgen Pilz; Andrea Rodenbeck; Kolja Schiltz; Edzard Schwedhelm; Hayrettin Tumani; Jens Wiltfang; Paul C Guest; Johann Steiner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-12-02       Impact factor: 5.270

2.  Risperidone Reduces Matrix Metalloproteinase-9 and Increases Neurotrophin-3 in Schizophrenia Spectrum of Disorder.

Authors:  Raghavi Chenniappan; Hanumanthappa Nandeesha; Shivanand Kattimani; Alladi Charanraj Goud; Durgadevi Thiagarajan
Journal:  Indian J Clin Biochem       Date:  2021-06-21

3.  Matrix Metalloproteinase 9 Blood Alterations in Patients With Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis.

Authors:  Georgios Schoretsanitis; Renato de Filippis; Maria Ntogka; Stefan Leucht; Christoph U Correll; John M Kane
Journal:  Schizophr Bull       Date:  2021-07-08       Impact factor: 9.306

4.  MMP-9 Serum Levels in Schizophrenic Patients during Treatment Augmentation with Sarcosine (Results of the PULSAR Study).

Authors:  Dominik Strzelecki; Olga Kałużyńska; Justyna Szyburska; Adam Wysokiński
Journal:  Int J Mol Sci       Date:  2016-07-09       Impact factor: 5.923

5.  Developmental disruption of perineuronal nets in the medial prefrontal cortex after maternal immune activation.

Authors:  John W Paylor; Brittney R Lins; Quentin Greba; Nicholas Moen; Reiner Silveira de Moraes; John G Howland; Ian R Winship
Journal:  Sci Rep       Date:  2016-11-23       Impact factor: 4.379

Review 6.  Neurovascular Unit Dysfunction and Blood-Brain Barrier Hyperpermeability Contribute to Schizophrenia Neurobiology: A Theoretical Integration of Clinical and Experimental Evidence.

Authors:  Souhel Najjar; Silky Pahlajani; Virginia De Sanctis; Joel N H Stern; Amanda Najjar; Derek Chong
Journal:  Front Psychiatry       Date:  2017-05-23       Impact factor: 4.157

7.  Obesity, altered oxidative stress, and clinical correlates in chronic schizophrenia patients.

Authors:  Huimei An; Xiangdong Du; Xingbing Huang; Lingyan Qi; Qiufang Jia; Guangzhong Yin; Chunling Xiao; Xu-Feng Huang; Yuping Ning; Ryan M Cassidy; Li Wang; Jair C Soares; Xiang Yang Zhang
Journal:  Transl Psychiatry       Date:  2018-11-29       Impact factor: 6.222

Review 8.  MMPs in learning and memory and neuropsychiatric disorders.

Authors:  Anna Beroun; Shiladitya Mitra; Piotr Michaluk; Barbara Pijet; Marzena Stefaniuk; Leszek Kaczmarek
Journal:  Cell Mol Life Sci       Date:  2019-06-06       Impact factor: 9.261

9.  Plasma levels of matrix metalloproteinase-9 (MMP-9) are associated with cognitive performance in patients with schizophrenia.

Authors:  Noriko Kudo; Hidenaga Yamamori; Tamaki Ishima; Kiyotaka Nemoto; Yuka Yasuda; Michiko Fujimoto; Hirotsugu Azechi; Tomihisa Niitsu; Shusuke Numata; Manabu Ikeda; Masaomi Iyo; Tetsuro Ohmori; Masaki Fukunaga; Yoshiyuki Watanabe; Kenji Hashimoto; Ryota Hashimoto
Journal:  Neuropsychopharmacol Rep       Date:  2020-02-05

10.  Thiol Disulfide Homeostasis in Schizophrenic Patients Using Atypical Antipsychotic Drugs.

Authors:  Halef Okan Dogan; Etem Erdal Ersan; Hüseyin Aydin; Serpil Erdoğan; Serpil Erşan; Murat Alişik; Sevtap Bakir; Özcan Erel; Derya Koç
Journal:  Clin Psychopharmacol Neurosci       Date:  2018-02-28       Impact factor: 2.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.